![](https://www.huntingtonsociety.ca/wp-content/uploads/2015/10/Blair-Levitt_UBC-New-test.png)
A new test developed by UBC researchers allows physicians to measure the effects of gene silencing therapy in Huntington’s disease and will support the first human clinical trial of a drug that targets the genetic cause of the disease.
A new test developed by UBC researchers allows physicians to measure the effects of gene silencing therapy in Huntington’s disease and will support the first human clinical trial of a drug that targets the genetic cause of the disease.